NYSE$UHS

Universal Health Services Inc · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

UHS's net income and revenues increased during the second quarter of 2024, with an increase in the full year operating results forecast and stock repurchase program authorization.

Universal Health Services, Inc. reported a strong second quarter in 2024, with net income attributable to UHS of $289.2 million, or $4.26 per diluted share, compared to $171.3 million, or $2.42 per diluted share, in the second quarter of 2023. Net revenues increased by 10.1% to $3.908 billion. The company also increased its full-year operating results forecast and announced a $1 billion increase to its stock repurchase program authorization.

  • Net income attributable to UHS was $289.2 million, or $4.26 per diluted share, during the second quarter of 2024.
  • Net revenues increased by 10.1% to $3.908 billion during the second quarter of 2024.
  • The company increased its operating results forecast range for consolidated net revenues, Adjusted EBITDA, and Adjusted EPS for the year ended December 31, 2024.
  • The Board of Directors authorized a $1.0 billion increase to the stock repurchase program.

Headline financials

Total Revenue

$3.91B

Previous: $3.55B+10.1%
EPS

$4.26

Previous: $2.53+68.4%
Avg Licensed Beds

6.8K

Previous: 6.6K+1.9%
Avg Available Beds

6.6K

Previous: 6.5K+2.0%
Patient Days

395.9K

Previous: 384.4K+3.0%
Avg Daily Census

4.4K

Previous: 4.2K+3.0%
Occupancy Licensed Beds

64.4%

Previous: 63.8%+0.9%
Occupancy Available Beds

66.1%

Previous: 65.5%+0.9%
Admissions

82.7K

Previous: 79.1K+4.6%
Length of Stay

4.8

Previous: 4.9-2.0%
BH Avg Licensed Beds

24.3K

Previous: 24.2K+0.6%
BH Avg Available Beds

24.2K

Previous: 24.1K+0.6%
BH Patient Days

1.6M

Previous: 1.6M+1.6%
BH Avg Daily Census

17.7K

Previous: 17.5K+1.6%
BH Occupancy Licensed

72.9%

Previous: 72.2%+1.0%
BH Occupancy Available

73.2%

Previous: 72.5%+1.0%
BH Admissions

118.9K

Previous: 119.7K-0.6%
BH Length of Stay

13.6

Previous: 13.3+2.3%
Capital Expenditures

-$450M

Previous: -$337M-33.6%
Free Cash Flow

-$161M

Previous: -$165M+2.8%
Net Income

$289M

Previous: $171M+68.8%
Operating Income

$436M

Previous: $280M+55.8%
Cash & Equivalents

$129M

Previous: $79.5M+62.1%
Total Assets

$14.1B

Previous: $13.7B+2.5%
Stock-Based Comp

$26.5M

Previous: $22.1M+20.1%

Revenue & EPS history

UHS · Revenue · Quarterly

$3.91B

Q2 2024+10.1%vs Q2 2023
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

UHS · $3.56B total across 2 segments · Q3 2023

  • Acute Care Services
    $2.02B+5.1%
  • Behavioral Health Services
    $1.54B+7.5%

Forward guidance

Based upon the operating trends and financial results experienced during the first six months of 2024, the company is increasing its operating results forecast range for consolidated net revenues; adjusted earnings before interest, taxes, depreciation & amortization, and the impacts of other income/expense and net income attributable to noncontrolling interests and adjusted net income attributable to UHS per diluted share for the year ended December 31, 2024.

Tailwinds

  • Revised 2024 forecasted net revenues are estimated to be approximately $15.565 billion to $15.753 billion, representing increases of 1.0% to 0.3% over our original 2024 forecasted net revenues.
  • Revised 2024 forecasted Adjusted EBITDA, net of NCI, is estimated to be approximately $2.154 billion to $2.226 billion, representing increases of 11.5% to 10.3% over our original 2024 forecasted Adjusted EBITDA, net of NCI.
  • Revised 2024 forecasted Adjusted EPS-diluted is estimated to be $15.40 per share to $16.20 per share, representing increases of 18.5% to 15.7% over our original 2024 forecasted Adjusted EPS-diluted.
  • The company's revised forecast reflects strong operating trends and financial results from the first six months of 2024.
  • The increased forecast indicates confidence in the company's ability to continue its growth trajectory.

Headwinds

  • The forecasted amounts exclude the impact of future items that are nonrecurring or non-operational in nature.
  • The forecast is subject to conditions including those set forth in General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures.
  • A significant portion of the company's revenues are derived from federal and state government programs, which are subject to change.
  • The increase in interest rates has substantially increased the company's borrowings costs and reduced its ability to access the capital markets on favorable terms.
  • The outcome of known and unknown litigation, liabilities and other claims asserted against the company and/or its subsidiaries could have a material adverse effect.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

+0.3%

Avg return

Earnings day

+0.3%

Avg return

5 days after

+0.7%

Avg return

30 days after

49%

34 / 69 earnings

Positive

+17.5%

Q3 2022

Best reaction

-13.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-9.5%-7.0%-16.4%
Q4 2025-5.5%-1.0%-9.9%
Q3 2025+2.5%+1.4%+14.1%
Q2 2025-0.2%+3.3%+7.3%
Q1 2025-0.6%+3.4%+10.5%
Q4 2024+3.3%-3.8%+3.4%
Q3 2024-13.4%-12.1%-15.5%
Q2 2024+10.6%+17.3%+25.8%
Q1 2024+0.1%+2.6%+6.9%
Q4 2023-1.6%+4.1%+11.0%
Q3 2023-0.2%-0.6%+11.4%
Q2 2023-4.6%-6.5%-12.3%
Q1 2023+1.5%+6.9%-9.3%
Q4 2022-9.1%-13.5%-15.5%
Q3 2022+17.5%+25.8%+39.3%
Q2 2022-1.5%+1.3%-5.7%
Q1 2022-5.7%-7.8%-8.1%
Q4 2021+8.6%+8.7%+11.1%
Q3 2021-7.0%-8.5%-5.0%
Q2 2021+4.2%+5.1%+1.6%
Q1 2021+0.3%+2.0%+10.1%
Q4 2020-9.1%-6.2%-2.0%
Q3 2020+3.0%+11.1%+24.2%
Q2 2020+0.9%+1.7%+0.2%
Q1 2020+3.7%-2.5%+8.6%
Q4 2019-5.3%-2.7%-34.3%
Q3 2019-4.6%-4.0%-3.6%
Q2 2019+10.9%+11.6%+4.7%
Q1 2019-0.8%-2.6%-5.5%
Q4 2018+3.9%+2.7%+0.1%
Q3 2018-5.3%-1.0%+8.0%
Q2 2018+9.3%+9.3%+12.0%
Q1 2018-4.6%-5.2%-3.2%
Q4 2017-1.3%+5.3%+0.7%
Q3 2017-6.9%-8.3%-9.9%
Q2 2017-9.2%-10.3%-12.6%
Q1 2017-2.0%-0.1%-3.0%
Q4 2016-0.9%-0.8%-0.8%
Q3 2016+0.6%-0.7%+1.3%
Q2 2016-4.4%-5.2%-12.1%
Q1 2016+2.1%
Q4 2015+2.4%
Q3 2015+2.4%
Q2 2015+2.1%
Q1 2015-0.7%
Q4 2014+3.8%
Q3 2014-1.0%
Q2 2014+6.8%
Q1 2014+8.3%
Q4 2013-2.6%
Q3 2013+2.6%
Q2 2013+3.3%
Q1 2013+3.3%
Q4 2012-0.0%
Q3 2012-3.2%
Q2 2012+4.8%
Q1 2012-1.7%
Q2 2011+2.0%
Q4 2011+2.0%
Q3 2011+3.8%
Q1 2010+3.8%
Q4 2010+3.8%
Q1 2011+3.8%
Q2 2010+5.0%
Q3 2009+0.0%
Q3 2010+0.0%
Q4 2009-0.3%
Q2 2009-0.3%
Q4 2008-0.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro